Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quemliclustat - Arcus Biosciences

Next Previous
X
Search
Drug Profile

Quemliclustat - Arcus Biosciences

Alternative Names: AB-680; Small molecule CD73 inhibitor - Arcus Biosciences

Latest Information Update: 10 Mar 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arcus Biosciences
  • Developer Arcus Biosciences; Gilead Sciences; UCLAs Jonsson Comprehensive Cancer Center
  • Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Fluorobenzenes; Phosphonic acids; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action 5-nucleotidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Adenocarcinoma
  • Phase II Cholangiocarcinoma; Non-small cell lung cancer
  • Phase I/II Colorectal cancer
  • No development reported Cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 13 Dec 2024 Phase-III clinical trials in Adenocarcinoma (First-line therapy, Combination therapy, Metastatic disease) in Spain, South Korea, Japan, Italy, France, Austria, Australia (IV) (NCT06608927)
  • 30 Nov 2024 Phase-III clinical trials in Adenocarcinoma (First-line therapy, Combination therapy, Metastatic disease) in USA (IV) (NCT06608927)
  • 03 Oct 2024 Arcus Biosciences plans the phase III PRISM-1 trial in Adenocarcinoma (Metastatic disease, Combination therapy, First line therapy) (IV, Infusion) (NCT06608927) (EUCT2024-513317-12-00)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top